{"id":66209,"date":"2026-05-25T21:36:52","date_gmt":"2026-05-25T13:36:52","guid":{"rendered":"https:\/\/flcube.com\/?p=66209"},"modified":"2026-05-25T21:36:53","modified_gmt":"2026-05-25T13:36:53","slug":"novo-nordisk-secures-chmp-positive-opinion-for-wegovy-7-2-mg-single-dose-pen-and-oral-semaglutide-in-eu-obesity-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66209","title":{"rendered":"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Novo Nordisk A\/S (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>)<\/strong> announced that the <strong>Committee for Medicinal Products for Human Use (CHMP)<\/strong> of the <strong>European Medicines Agency (EMA)<\/strong> has adopted a <strong>positive opinion<\/strong>, recommending marketing authorization for two formulations of <strong>Wegovy (semaglutide)<\/strong> for obesity treatment: the <strong>7.2 mg single-dose pen<\/strong> and the <strong>once-daily oral tablet (25 mg)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestones-amp-product-portfolio\" class=\"wp-block-heading\">Regulatory Milestones &amp; Product Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Formulation<\/th><th>Current EU Status<\/th><th>Global Availability<\/th><th>Expected EU Launch<\/th><\/tr><\/thead><tbody><tr><td><strong>Wegovy 7.2 mg<\/strong><\/td><td>Once-weekly injectable single-dose pen<\/td><td>CHMP positive opinion<\/td><td>Approved in US (as Wegovy HD) and UK<\/td><td>Q3 2026<\/td><\/tr><tr><td><strong>Wegovy pill<\/strong><\/td><td>Once-daily oral semaglutide 25 mg<\/td><td>CHMP positive opinion<\/td><td>Not yet available outside US<\/td><td>H2 2026 (select markets)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-clinical-evidence-amp-efficacy-data\" class=\"wp-block-heading\">Clinical Evidence &amp; Efficacy Data<\/h2>\n\n\n\n<h3 id=\"h-step-up-trial-programme-wegovy-7-2-mg-injection\" class=\"wp-block-heading\">STEP UP Trial Programme \u2013 Wegovy 7.2 mg Injection<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mean Weight Loss:<\/strong> 20.7% in participants with obesity<\/li>\n\n\n\n<li><strong>Dosing Regimen:<\/strong> Once-weekly 7.2 mg injection (single-dose pen)<\/li>\n\n\n\n<li><strong>Comparison:<\/strong> Previously available as three separate 2.4 mg injections totaling 7.2 mg weekly dose<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-oasis-amp-select-trial-programmes-wegovy-oral-tablet\" class=\"wp-block-heading\">OASIS &amp; SELECT Trial Programmes \u2013 Wegovy Oral Tablet<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Weight Loss Efficacy:<\/strong> Comparable to injectable Wegovy 2.4 mg<\/li>\n\n\n\n<li><strong>Cardiovascular Benefits:<\/strong> <strong>SELECT trial data<\/strong> demonstrates significant reduction in <strong>major adverse cardiovascular events (MACE)<\/strong><\/li>\n\n\n\n<li><strong>Label Inclusion:<\/strong> CHMP positive opinion includes SELECT cardiovascular risk reduction data in product labeling<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-expansion-strategy\" class=\"wp-block-heading\">Market Expansion Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Novo Nordisk&#8217;s dual-track approach addresses different patient preferences and treatment adherence challenges:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Injectable 7.2 mg pen:<\/strong> Simplifies administration compared to previous multi-injection regimen<\/li>\n\n\n\n<li><strong>Oral 25 mg tablet:<\/strong> Offers needle-free option with proven efficacy equivalent to established injectable doses<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The company plans a <strong>phased EU rollout<\/strong> beginning with the injectable formulation in Q3 2026, followed by oral tablet launch in select international markets in the second half of 2026. The inclusion of <strong>cardiovascular risk reduction data<\/strong> in the oral formulation&#8217;s label represents a significant competitive advantage, positioning Wegovy as both a weight management and cardiovascular protective therapy.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-commercial-impact\" class=\"wp-block-heading\">Competitive Landscape &amp; Commercial Impact<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">With obesity affecting over <strong>59 million adults in the EU<\/strong>, Novo Nordisk&#8217;s expanded Wegovy portfolio addresses a substantial unmet medical need. The <strong>20.7% mean weight loss<\/strong> demonstrated by the 7.2 mg formulation significantly exceeds results from competing GLP-1 therapies, while the oral option removes a key barrier to treatment initiation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The cardiovascular benefits validated in the SELECT trial further differentiate Wegovy from competitors lacking robust outcome data, potentially influencing reimbursement decisions and clinical guidelines across European healthcare systems.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, product launches, clinical outcomes, and commercial expectations. Actual results may differ due to risks including final regulatory decisions, market competition, manufacturing capacity, and pricing negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use&#8230;<\/p>\n","protected":false},"author":1,"featured_media":66210,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[38,148,860,86],"class_list":["post-66209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-approval-filings","tag-novo-nordisk","tag-nyse-nvo","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for two formulations of Wegovy (semaglutide) for obesity treatment: the 7.2 mg single-dose pen and the once-daily oral tablet (25 mg).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66209\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for two formulations of Wegovy (semaglutide) for obesity treatment: the 7.2 mg single-dose pen and the once-daily oral tablet (25 mg).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66209\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-25T13:36:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-25T13:36:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/25-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment\",\"datePublished\":\"2026-05-25T13:36:52+00:00\",\"dateModified\":\"2026-05-25T13:36:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209\"},\"wordCount\":417,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/25-1.webp\",\"keywords\":[\"Market approval filings\",\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66209#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66209\",\"name\":\"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/25-1.webp\",\"datePublished\":\"2026-05-25T13:36:52+00:00\",\"dateModified\":\"2026-05-25T13:36:53+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for two formulations of Wegovy (semaglutide) for obesity treatment: the 7.2 mg single-dose pen and the once-daily oral tablet (25 mg).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66209\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/25-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/25-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66209#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for two formulations of Wegovy (semaglutide) for obesity treatment: the 7.2 mg single-dose pen and the once-daily oral tablet (25 mg).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66209","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment","og_description":"Novo Nordisk A\/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for two formulations of Wegovy (semaglutide) for obesity treatment: the 7.2 mg single-dose pen and the once-daily oral tablet (25 mg).","og_url":"https:\/\/flcube.com\/?p=66209","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-25T13:36:52+00:00","article_modified_time":"2026-05-25T13:36:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/25-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66209#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66209"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment","datePublished":"2026-05-25T13:36:52+00:00","dateModified":"2026-05-25T13:36:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66209"},"wordCount":417,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=66209#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/25-1.webp","keywords":["Market approval filings","Novo Nordisk","NYSE: NVO","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66209#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66209","url":"https:\/\/flcube.com\/?p=66209","name":"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=66209#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=66209#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/25-1.webp","datePublished":"2026-05-25T13:36:52+00:00","dateModified":"2026-05-25T13:36:53+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for two formulations of Wegovy (semaglutide) for obesity treatment: the 7.2 mg single-dose pen and the once-daily oral tablet (25 mg).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66209#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66209"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=66209#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/25-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/25-1.webp","width":1080,"height":608,"caption":"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66209#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Secures CHMP Positive Opinion for Wegovy 7.2 mg Single-Dose Pen and Oral Semaglutide in EU Obesity Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/25-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66209"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66209\/revisions"}],"predecessor-version":[{"id":66211,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66209\/revisions\/66211"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/66210"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}